| Date | Title | Description | Source |
| 30.04.2024 | Innovent Announces the Appointment of Dr. Samuel Zhang as Gl... | SAN FRANCISCO and SUZHOU, China, April 30, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Inno... | en.prnasia... |
| 16.04.2024 | Innovent Announces the Appointment of Dr. Nageatte Ibrahim a... | SAN FRANCISCO and SUZHOU, China, April 16, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Inno... | en.prnasia... |
| 08.04.2024 | Innovent to Present Preclinical Data of Multiple Novel Molec... | ROCKVILLE, Md. and SUZHOU, China, April 8, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Inno... | en.prnasia... |
| 20.03.2024 | Innovent Announces 2023 Annual Results and Business Updates | A transformative year of strong performance and material innovation progress
ROCKVILLE, M.D. and SUZ... | en.prnasia... |
| 19.03.2024 | Innovent Announces Primary Endpoint Met in the Second Phase ... | ROCKVILLIE, Md. and SUZHOU, China, March 19, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("In... | en.prnasia... |
| 12.03.2024 | Innovent to Present Preclinical Data of Multiple Novel Molec... | ROCKVILLE, Md. and SUZHOU, China, March 12, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Inn... | en.prnasia... |
| 05.03.2024 | Incyte Launches ‘The Unseen Journey’ to Elevate Impact of MP... | The Unseen Journey brings to life the often-misunderstood impact of common myeloproliferative neopla... | aithority.... |
| 04.03.2024 | Growth Trajectory Of Merkel Cell Carcinoma Treatment Market:... | Exclusive Offer By The Business Research Company - Get 33% Discount On Opportunities And Strategies ... | einpresswi... |
| 04.10.2022 | Incyte to Acquire Villaris Therapeutics | Incyte (NASDAQ:INCY), a Wilmington, DE-based biopharmaceutical company, acquired Villaris Therapeuti... | finsmes.co... |
| 22.03.2022 | MorphoSys and Incyte Announce Swissmedic Temporary Approval ... | MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combinati... | accesswire... |
| 28.01.2022 | Updates on OLUMIANT® (baricitinib) Phase 3 lupus program and... | INDIANAPOLIS, Jan. 28, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INC... | marketscre... |
| 30.09.2021 | Incyte : OLUMIANT® Significantly Improved Hair Regrowth to A... | INDIANAPOLIS, Sept. 30, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: I... | marketscre... |
| 03.08.2021 | Incyte : Lilly and Incyte's baricitinib reduced deaths among... | INDIANAPOLIS, Aug. 3, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY... | marketscre... |
| 29.07.2021 | Eli Lilly and : FDA broadens existing emergency use of Lilly... | INDIANAPOLIS, July 29, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INC... | marketscre... |
| 28.07.2021 | Incyte : Announces Progress on Global Responsibility Initiat... | ∙
∙
∙
∙
2
Attachments
Original document
Permalink
Disclaimer
Incyte Corporation published this conte... | marketscre... |
| 02.07.2021 | PACT held its annual Enterprise Awards IRL this week. Here’s... | For the first time in about a year and a half, the Philadelphia Alliance for Capital and Technologie... | technical.... |
| 02.06.2021 | INCYTE CORPORATION
Incyte : OLUMIANT® Improved Pain, Physic... | INDIANAPOLIS, June 1, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INC... | marketscre... |
| 28.05.2021 | BB Biotech : investment trust review highlights long t... | Launched in 1993, BB Biotech (BION) is one of the largest specialist funds investing in the fast-gro... | marketscre... |
| 08.04.2021 | Eli Lilly and : Lilly and Incyte announce results from the P... | INDIANAPOLIS, April 8, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INC... | marketscre... |
| 11.03.2021 | Incyte Announces Data from Multiple Programs Within its Onco... | WILMINGTON, Del.--(BUSINESS WIRE)--Mar 11, 2021--
Incyte (Nasdaq:INCY) today announced that multiple... | oaoa.com/n... |
| 11.02.2021 | MacroGenics Announces Achievement of $10 Million Milestone R... | ROCKVILLE, MD, Feb. 11, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutic... | globenewsw... |
| 12.11.2020 | British biopharmaceutical company Grow Group PLC announces G... | | prnewswire... |
| 15.09.2020 | US based biopharmaceutical company Attralus raises US$ 25M S... | - | vcbay.news... |
| 11.03.2020 | Biopharmaceutical Company Amunix Closes $73 Million In Fundi... | Amunix Pharmaceuticals, a biopharmaceutical company focused on developing prodrugs, announced it rai... | pulse2.com... |
| 30.09.2019 | Agios drug improves progression-free survival in Phase III c... | A drug used to treat a form of adult leukemia has shown efficacy in a form of bile duct cancer that ... | medcitynew... |
| 18.08.2019 | FDA approves first drug for blood disorder myelofibrosis sin... | Prior to Inrebic’s approval, the only drug approved for myelofibrosis was Incyte’s Jakafi (ruxolitin... | medcitynew... |
| 08.02.2017 | As hep C revenues decline, investors ask: Who is Gilead? | Sales of its chronic hepatitis C virus (HCV) treatments decreased from over $19 billion in 2015 to a... | medcitynew... |
| 07.10.2016 | Updated Incyte combo data for epacadostat/Keytruda l... | Incyte this morning teed up a fresh look at data from its early-stage study of its closely watc... | endpts.com... |
| 28.09.2016 | Incyte’s IDO1 update on its Keytruda combo scores some p... | Incyte’s latest cut on the data from a Phase I/II study of its combination therapy adding Me... | endpts.com... |
| 08.04.2016 | Incyte snags rights to blood disease drug | The Wilmington-based biopharmaceutical company Incyte Corporation announced this week that it has bo... | technical.... |
| 08.04.2016 | Incyte snags rights to blood disease drug | The Wilmington-based biopharmaceutical company Incyte Corporation announced this week that it has bo... | technical.... |
| 21.07.2015 | Kris Vaddi is ditching big pharma for the startup life | If you ask Kris Vaddi, he’ll tell you the best time at Incyte Corp. was when the pharmaceutical comp... | technical.... |
| 04.05.2015 | These bioscience pros were honored at the Delaware Bio Award... | Hundreds of professionals across multiple industries gathered at the DuPont Country Club in Wilmingt... | technical.... |
| 16.03.2015 | Newark’s trending right now [Events Roundup] | Newark has two great events happening this week: Delaware BioScience Association’s career fair with ... | technical.... |
| 11.11.2014 | 13 innovative technologies being developed in Delaware | The Delaware technology community may still be new to building web and software businesses. Its medi... | technical.... |
| 09.11.2012 | 5 things for startups to consider as they walk tightrope tow... | Make sure you describe your company’s device or drug accurately Years before Capper joined CardioNet... | medcitynew... |
| 08.06.2012 | Lilly’s rheumatoid arthritis drug using JAK inhibitors gets ... | Among the findings were baricitinib at 4 milligrams and 8 milligrams QD improved the signs and sympt... | medcitynew... |
| 20.04.2012 | EU recommendation triggers $40M milestone payment for bone m... | Known as Jakafi in the U.S., the drug was approved by the U.S. Food and Drug Administration in Novem... | medcitynew... |
| - | Agios drug improves progression-free survival in Phase III c... | A drug used to treat a form of adult leukemia has shown efficacy in a form of bile duct cancer that ... | medcitynew... |
| - | FDA approves first drug for blood disorder myelofibrosis sin... | The Food and Drug Administration has approved the first new drug for a type of rare blood cancer in ... | medcitynew... |
| - | Incyte Announces the Validation by the European Medicines Ag... | WILMINGTON, Del.--(BUSINESS WIRE)--Feb 26, 2021--
Incyte (Nasdaq:INCY) today announced the validatio... | oaoa.com/n... |
| - | As hep C revenues decline, investors ask: Who is Gilead? | Despite overdelivering on fourth quarter 2016 earnings, shares of Gilead Sciences dropped six points... | medcitynew... |
| - | EU recommendation triggers $40M milestone payment for bone m... | A European Union regulatory committee’s recommendation to approve a drug developed by Incyte (NASDAQ... | medcitynew... |
| - | Incyte Announces Results from the Phase 3 DEVENT Study Evalu... | WILMINGTON, Del.--(BUSINESS WIRE)--Mar 18, 2021--
Incyte (Nasdaq:INCY) today announced results from ... | oaoa.com/n... |
| - | Lilly’s rheumatoid arthritis drug using JAK inhibitors gets ... | Eli Lilly‘s (NYSE:LLY) rheumatoid arthritis treatment developed by drug developer Incyte (NASDAQ:INC... | medcitynew... |
| - | 5 things for startups to consider as they walk tightrope tow... | There are benefits for startup medical device and drug development companies to court regulators lik... | medcitynew... |
